The 1200 Patients Project: Studying the Implementation of Clinical Pharmacogenomic Testing
| Status: | Recruiting |
|---|---|
| Conditions: | Cancer, Irritable Bowel Syndrome (IBS), Peripheral Vascular Disease, Cardiology, Infectious Disease, Endocrine, Gastrointestinal, Hepatitis, Hematology |
| Therapuetic Areas: | Cardiology / Vascular Diseases, Endocrinology, Gastroenterology, Hematology, Immunology / Infectious Diseases, Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 1/13/2018 |
| Start Date: | January 14, 2011 |
| End Date: | December 2018 |
| Contact: | 1200 Patients Project Study Team |
| Email: | cpt1200@uchicago.edu |
| Phone: | (773) 834-1759 |
The purpose of this study is to collect DNA samples from patients undergoing routine care at
the University of Chicago. These samples will be tested for differences in genes that may
suggest greater risk of side effects or chance of increased benefit from certain medications.
The results will be made available to the patient's treating physician and the researchers
will track whether or not this information is used in routine health care.
the University of Chicago. These samples will be tested for differences in genes that may
suggest greater risk of side effects or chance of increased benefit from certain medications.
The results will be made available to the patient's treating physician and the researchers
will track whether or not this information is used in routine health care.
Inclusion Criteria:
- Receiving ongoing, out-patient care at the University of Chicago Medical Center under
the routine care of a physician participating in this trial
- Life expectancy of at least 3 years
- Must be 18 years or older
- Must be taking at least 1 (but not more than 6) prescription medications at the time
of enrollment OR be 65 years or older OR be reasonably expected to require the use of
a prescription medication within the next 5 years
- Patients with certain diseases, or likely to receive or be receiving certain drugs,
will be targeted particularly for enrollment in order to enrich the study for patients
likely to have pharmacogenetically relevant interactions, including, but not limited
to:
- Patients requiring specialized cardiology care
- Patients with inflammatory bowel diseases
- Patients with systemic autoimmune or inflammatory diseases
- Patients requiring long-term oral anticoagulation
- Patients with hepatitis C
- Patients with non-metastatic cancer
Exclusion Criteria:
- Patients with acute or chronic disease which could be reasonably expected to result in
the patient's death within the next 3 years.
- Patients who have undergone, or are being actively considered for, liver or kidney
transplantation.
- Inability to understand and give informed consent to participate.
We found this trial at
1
site
University of Chicago Medical Center The University of Chicago Medicine has been at the forefront...
Click here to add this to my saved trials
